Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) has extended the closing date of its Share Purchase Plan (SPP) to 5.00 pm (AEST) on Tuesday, July 22, 2025, to give eligible shareholders additional time to participate in the offer. The SPP aims to raise up to A$7 million to progress lead candidate PTX-100 through Phase 2 clinical development towards potential regulatory approval.
The SPP offers new fully paid ordinary shares at A$0.040 each — a 16.7% discount to the 15-day volume weighted average price prior to the SPP announcement. Eligible shareholders as at 7.00 pm (AEST) on Monday, June 30, 2025 may apply for up to A$30,000 worth of shares.
The offer price of A$0.040 per share reflects a significant discount designed to encourage shareholder participation.
An updated SPP timetable includes the revised share issue date of July 30, 2025 and the start of trading on July 31, 2025.
Use of funds: Advancing PTX-100
Funds raised through the SPP will support the continued clinical development of PTX-100, Prescient’s lead targeted therapy.
PTX-100, a first-in-class inhibitor of geranylgeranyl transferase-1 (GGT-1), has demonstrated promising safety and efficacy in early studies.
A Phase 2a trial in cutaneous T-cell lymphoma (CTCL) is underway, with up to 40 patients expected to enrol. PTX-100 has received both Orphan Drug and Fast Track Designations from the United States Food and Drug Administration (FDA).
Company overview and broader pipeline
Prescient is a clinical-stage oncology company advancing targeted and personalised cancer therapies. Beyond PTX-100, the company is developing several next-generation cell therapy platforms:
- CellPryme-M: A manufacturing-stage enhancement for adoptive cell therapies to improve tumour targeting and persistence.
- CellPryme-A: An adjuvant administered with cell therapies to mitigate tumour-induced immune suppression and bolster treatment efficacy.
- OmniCAR: A modular and universal CAR-T platform allowing precise, on-demand, multi-antigen targeting.
These platforms are designed to complement and improve current cell therapy strategies across solid and haematological cancers.
Read more: Prescient Therapeutics targets potential in cancer treatment with PTX-100
Upcoming webinar
Join Prescient Therapeutics CEO James McDonnell for a live, interactive shareholder briefing on Thursday, July 17, at 12:00 pm (AEST).
The session will cover details of the current SPP, the proposed use of funds and how shareholders can take part.
Register here: https://prescienttherapeutics.investorportal.com.au/shareholder-briefing-spp/